Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof

US8987285B2 · kind B2 · utility

Assignee

• Portola Pharmaceuticals, Inc. · US

Inventors

• Ulrich Meier · Wetzikon, CH
• Nicole Bieri · Zürich, CH
• Dieter Becker · Neunburg vorm Wald, DE
• Julien Taillemite · Huningue, FR
• Marie-Pierre Filliot · Geispitzen, FR
• Tanja Meister · Rheinfelden (Baden), DE

Key dates

• Filing date: Dec 5, 2011
• Grant date: Mar 24, 2015
• Expiry date: Dec 5, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.